Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06590662 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Name: Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia. — clinical trial record (NCT06590662)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: SOLR-IH

StatusNot Yet Recruiting

PhasePhase 2

SponsorUniversity Hospital, Montpellier

Started2024-09-15

View on ClinicalTrials.gov ↗

University Hospital, Montpellier

303 trials monitored

See 6 trials at risk

This Phase II clinical trial is a monocenter, double-blind, randomized, placebo-controlled study aimed at evaluate the efficacy and safety of solriamfetol from 75 to 300 mg per day in IH patients. Patients will be randomized (1:1) to receive either solriamfetol or placebo, with titration, every morning upon awakening during all treatment periods (Day 0 to Week 7).

Trial Details

NCT Number	NCT06590662
Lead Sponsor	University Hospital, Montpellier
Conditions	Idiopathic Hypersomnia
Enrollment	60 participants
Start Date	2024-09-15
Primary Completion	2026-11-15 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-09-19